Also listed on Novartis AG, an earlier holder on the record. The recorded assignments below show how it moved.
Term ends Nov 27, 2026 · Medium confidence
20-year base term ends Nov 27, 2026
Why Medium: A parent in the chain could not be resolved.
Held by GlaxoSmithKline Biologicals S.A.
Filed Mar 18, 2013 as application 13/845,305 · Granted Oct 13, 2015
Base term, 20 years from filing
Today
2006
2026
Clock starts
Nov 27, 2006
Nov 27, 2006
Term ends
Nov 27, 2026
Nov 27, 2026
Granted
Oct 13, 2015
Oct 13, 2015
base term
fee events
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
2 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
4
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. 2 of 2 maintenance fees are paid so far. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Nov 27, 2006, when application PCT/IB2006/003876, the earliest non-provisional in its chain, was filed (this one was filed Mar 18, 2013); a parent in its chain could not be resolved (the next row) | Nov 27, 2026 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 2 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Nov 27, 2026 | Medium confidence |
Partial family
| Application PCT/IB2006/003876 | PCT application no patent term | no patent term |
| US 8,226,960 | Lapsed on the fee record Jul 2020 | Jul 2020 |
| US 8,398,999 | Lapsed on the fee record Mar 2021 | Mar 2021 |
| US 9,156,894 | this patent Nov 2026 | Nov 2026 |
Partial: 1 of the 4 has no file history here, so its row comes from the patent's own record or names the application alone. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jul 14, 2016 Reel 39162, frame 523 | Masignani, Vega; Scarselli, Maria; Rappuoli, Rino; Pizza, Mariagrazia; Giuliani, Marzia Monica | Novartis Vaccines and Diagnostics SRL | Assignment of Assignor's Interest |
| Jul 14, 2016 Reel 39162, frame 530 | Novartis Vaccines and Diagnostics SRL | Novartis AG | Assignment of Assignor's Interest |
| Jul 14, 2016 Reel 39348, frame 942 | Novartis AG | GlaxoSmithKline Biologicals S.A. | Assignment of Assignor's Interest |
| Oct 20, 2016 Reel 40077, frame 814 | Novartis Vaccines and Diagnostics SRL | GlaxoSmithKline Biologicals S.A. | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Nov 2026
Term ends Nov 27, 2026. No further fees fall due before then
Citations
14
later US patents cite this one
That is above the median of utility patents granted in 2015 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.